{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T04:12:24Z","timestamp":1781151144770,"version":"3.54.1"},"reference-count":30,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T00:00:00Z","timestamp":1676419200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001238","name":"Society of Hospital Pharmacists of Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001238","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>The infection risk in patients receiving ibrutinib, idelalisib or venetoclax for chronic lymphocytic leukaemia (CLL) or B\u2010cell lymphoma treated outside of clinical trials is incompletely defined. We sought to identify the severe infection rate and associated risk factors in a \u2018real\u2010world\u2019 cohort.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a retrospective cohort study of adult patients with CLL or lymphoma treated with ibrutinib, idelalisib or venetoclax.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 67 patients identified (ibrutinib <jats:italic>n<\/jats:italic>\u00a0=\u00a053, idelalisib <jats:italic>n<\/jats:italic>\u00a0=\u00a08 and venetoclax <jats:italic>n<\/jats:italic>\u00a0=\u00a06), 32 (48%) experienced severe infection. Severe infection occurred at a rate of 65 infections per 100 person\u2010years, with a median of 17.8\u00a0months of therapy. Median time to first infection (IQR) was 5.4\u00a0months (1.4\u201315.9). Poor baseline Eastern Cooperative Oncology Group (ECOG) performance status and high Charlson Comorbidity Index (CCI) score associated with increased risk of severe infection [hazard ratios (95% CI) 1.57 (1.07\u20132.31, <jats:italic>p<\/jats:italic>\u00a0=\u00a0.018) and 1.3 (1.05\u20131.62, <jats:italic>p<\/jats:italic>\u00a0=\u00a0.016) respectively].<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The severe infection rate for patients receiving ibrutinib, idelalisib or venetoclax for lymphoma and CLL exceeded those reported in clinical trials. Patients with poor ECOG or high CCI should be closely monitored for early signs of infection and prevention strategies actively pursued. Further prospective research is required to define optimal antimicrobial prophylaxis recommendations.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ejh.13928","type":"journal-article","created":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T14:33:22Z","timestamp":1674138802000},"page":"540-547","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["High risk of infection in \u2018real\u2010world\u2019 patients receiving ibrutinib, idelalisib or venetoclax for mature B\u2010cell leukaemia\/lymphoma"],"prefix":"10.1111","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7992-2838","authenticated-orcid":false,"given":"Amanda","family":"Tey","sequence":"first","affiliation":[{"name":"Pharmacy Department Monash Health  Clayton Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7894-3880","authenticated-orcid":false,"given":"James","family":"Schwarer","sequence":"additional","affiliation":[{"name":"Monash Infectious Diseases Monash Health  Clayton Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9142-0195","authenticated-orcid":false,"given":"Robert","family":"Raffa","sequence":"additional","affiliation":[{"name":"Pharmacy Department Monash Health  Clayton Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4884-7334","authenticated-orcid":false,"given":"Emily","family":"Shi","sequence":"additional","affiliation":[{"name":"Pharmacy Department Monash Health  Clayton Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1263-7255","authenticated-orcid":false,"given":"Eldho","family":"Paul","sequence":"additional","affiliation":[{"name":"Monash Centre for Health Research and Implementation, School of Public Health and Preventive Medicine Monash University  Clayton Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0308-6458","authenticated-orcid":false,"given":"Stephen","family":"Opat","sequence":"additional","affiliation":[{"name":"Department of Medicine, School of Clinical Sciences at Monash Health Monash University  Clayton Victoria Australia"},{"name":"Monash Haematology Monash Health  Clayton Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6642-5365","authenticated-orcid":false,"given":"Claire","family":"Dendle","sequence":"additional","affiliation":[{"name":"Monash Infectious Diseases Monash Health  Clayton Victoria Australia"},{"name":"Department of Medicine, School of Clinical Sciences at Monash Health Monash University  Clayton Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3185-6488","authenticated-orcid":false,"given":"Jake","family":"Shortt","sequence":"additional","affiliation":[{"name":"Department of Medicine, School of Clinical Sciences at Monash Health Monash University  Clayton Victoria Australia"},{"name":"Monash Haematology Monash Health  Clayton Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,2,15]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix687"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2018.04.007"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1177\/2049936121989548"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2018.03.004"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1347931"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-635326"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25638"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-04-639203"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-12-820910"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018028761"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13020"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy175"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.2038.2038"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2623"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2814"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30019-4"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30671-4"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.3994"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713976"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-3761"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1815281"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-021-04419-w"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/imj.15954"},{"key":"e_1_2_12_25_1","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0;2017; Accessed October 27 2021.https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021011568"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009966"},{"key":"e_1_2_12_31_1","first-page":"9","article-title":"Comparative analysis of BTK inhibitors and mechanisms underlying adverse effects","author":"Estupi\u00f1\u00e1n HY","year":"2021","journal-title":"Front Cell Dev Biol"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13928","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ejh.13928","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13928","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T20:24:45Z","timestamp":1692649485000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.13928"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,15]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.1111\/ejh.13928"],"URL":"https:\/\/doi.org\/10.1111\/ejh.13928","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,15]]},"assertion":[{"value":"2022-11-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}